Aaron Scott Mansfield
Leiden University · 585 works · 20,739 citations · h-index 57
Top works
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- Detection and localization of surgically resectable cancers with a multi-analyte blood test
- First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
- Integrating genomic features for non-invasive early lung cancer detection
- Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
- PD-1 Restrains Radiotherapy-Induced Abscopal Effect
- Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
- Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
- B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
- First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
- Current Diagnosis and Management of Small-Cell Lung Cancer
- Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
- Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
- An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer
- LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
- Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer